Reuters
27 Jul 2026, 07:01 UTC · 3h ago
AstraZeneca's rare disease drug misses main goal in late-stage trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
27 Jul 2026, 07:01 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
AstraZeneca's rare disease drug Ultomiris failed a late-stage trial for blood vessel complications following stem cell transplants. — Failure in a late-stage trial removes a potential revenue stream and indicates a setback for a key product's expansion.
-0.60This trial failure is part of a series of setbacks for AstraZeneca's pipeline throughout the current year. — Recurring pipeline failures increase investor concerns regarding the long-term growth trajectory and R&D effectiveness of the company.
-0.40Which stocks this story touches
The company's drug failed a late-stage trial, contributing to a series of pipeline setbacks.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1d ago
